An Open-Label, Single-Arm Multicenter Phase 1b/2 Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Combination with Pembrolizumab in Subjects with Metastatic Triple-Negative Breast Cancer (mTNBC)
Study of Safety and Efficacy of Eribulin in Combination with Pembrolizumab in Breast Cancer Patients
Sponsor: Eisai Inc.
Enrolling: Male and Female Patients
IRB Number: AAAP8952
U.S. Govt. ID: NCT01126736
Contact: Kevin Kalinsky MD MS: 212-305-1945 / kk2693@cumc.columbia.edu
Additional Study Information: The purpose of this study is to evaluate the effectiveness and safety of eribulin mesylate (eribulin) incombination with pembrolizumab in metastatic (spread of cancer from one part of body to another) triple-negative breast cancer (mTNBC).
This study is closed
Investigator
Kevin Kalinsky, MD, MS
Do You Qualify?
Have you been diagnosed with metastatic breast cancer? Yes No
Have you been previously treated with 0 to 2 lines of chemotherapy? Yes No
Do you have a tissue sample available or a new biopsy sample? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder



Cancel
For more information, please contact:
Kevin Kalinsky MD MS
kk2693@cumc.columbia.edu
212-305-1945
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE